Efficacy analyses per region showed hazard ratios similar to those of the whole intention-to-treat ( ITT ) population for progression-free survival ( ITT : 0.63 ; Asia : 0.68 ; other regions : 0.61 ) and overall survival ( ITT : 0.66 ; Asia : 0.64 ; other regions : 0.66 ) .